Santarus to market Cycloset in the U.S.

VeroScience LLC (Tiverton, R.I.) and partner S2 Therapeutics Inc. (Bristol, Tenn.) granted Santarus Inc. (NASDAQ:SNTS) exclusive rights in the U.S. to commercialize Type II diabetes drug Cycloset bromocriptine. The timed-release tablet was approved last year but has not been marketed. VeroScience and S2 said at the time that they planned to sublicense marketing rights to a third party. Santarus plans to launch the product in November. ...